Takeda Pharmaceutical's Depreciation & Amortization (CF) rose 71.57% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.0 billion, marking a year-over-year decrease of 43.27%. This contributed to the annual value of $5.0 billion for FY2025, which is 98.26% down from last year.
Per Takeda Pharmaceutical's latest filing, its Depreciation & Amortization (CF) stood at $1.2 billion for Q4 2025, which was up 71.57% from $1.3 billion recorded in Q3 2025.
Over the past 5 years, Takeda Pharmaceutical's Depreciation & Amortization (CF) peaked at $1.3 billion during Q1 2021, and registered a low of $1.2 billion during Q3 2022.
Over the past 5 years, Takeda Pharmaceutical's median Depreciation & Amortization (CF) value was $1.3 billion (recorded in 2025), while the average stood at $1.3 billion.
Data for Takeda Pharmaceutical's Depreciation & Amortization (CF) shows a peak YoY increase of 410.7% (in 2023) and a maximum YoY decrease of 687.19% (in 2023) over the last 5 years.
Over the past 5 years, Takeda Pharmaceutical's Depreciation & Amortization (CF) (Quarter) stood at $1.3 billion in 2021, then decreased by 3.37% to $1.3 billion in 2022, then grew by 1.08% to $1.3 billion in 2023, then dropped by 2.83% to $1.2 billion in 2024, then increased by 0.72% to $1.2 billion in 2025.
Its Depreciation & Amortization (CF) was $1.2 billion in Q4 2025, compared to $1.3 billion in Q3 2025 and $1.3 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value